British patients could end up not being able to access modern medicines if there is a “hard Brexit”, a think tank report endorsed by a former Conservative health minister warned on Wednesday.
Drugmakers currently use the European Medicines Agency as a one-stop-shop to get drugs licensed across Europe, but Britain is likely to drop out of that system if it severs EU ties and leaves the single market in a scenario dubbed “hard Brexit”.
Source: Reuters
Filed Under: Drug Discovery
